Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Inclusion Criteria:

relapsing form of MS
screening EDSS score 0 - 5.5, inclusive
at least one clinical relapse in the 12 months before screening
active disease, defined by set of MRI activity criteria
failed prior treatment with beta-interferons or glatiramer acetate

Exclusion Criteria:

signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or Hepatitis C or tuberculosis
known allergy to gadolinium-DTPA, and/or ingredients of the study drug formulation
pre-treatment with immunosuppressive or immunomodulatory drugs prior to screening within certain time frames